ADA 2025
This is the logo of the provider
ADA 2025 20 - 23 June 2025

Efficacy and Safety of CagriSema 2.4mg/2.4mg in Adults with Overweight/Obesity—The REDEFINE 1 and REDEFINE 2 Clinical Trials

Authors :

Donna H. Ryan1; Thomas A. Lutz2; Julio Rosenstock3; W. Timothy (Tim) Garvey4; Melanie J. Davies5; Sue D. Pedersen6; Louis J. Aronne7
Affiliations
View Details Hide Details
This is the logo of the provider
{{ getPageNum(PDFPage) }}
This is the logo of the provider
{{ getPageNum(PDFPage) }}
This is the logo of the provider
{{ getPageNum(PDFPage) }}
This is the logo of the provider
{{ getPageNum(PDFPage) }}
This is the logo of the provider
{{ getPageNum(PDFPage) }}
This is the logo of the provider
{{ getPageNum(PDFPage) }}
Keywords
Obesity
Congress oral presentation
GLP-1 RA
CagriSema
PHASE 3 (RCT)